The pandemic continues to cause unprecedented disruption across industries worldwide.
Get detailed insights regarding the impact of COVID-19 on the market.
The global cord blood banking services market reached a value of US$ 1.48 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 2.83 Billion by 2027, exhibiting a CAGR of 11.20% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
Cord blood banking is a procedure of collecting and storing life-saving stem cells from the umbilical cord and placenta for future use. It uses hematopoietic stem cells that are present in the cord blood of the baby to develop it into red blood cells (RBCs), white blood cells (WBCs) and platelets. It aids in the treatment of cancer, blood diseases and immune system disorders as cord blood banking is less complicated, painful and risky for the donor compared to the collection of stem cells from bone marrow. As a result, it finds extensive applications in hospitals, research institutes, and specialty clinics.
The growing prevalence of different cancers, such as lymphoma and leukemia, due to longer working hours, stressful lives, and excessive smoking and alcohol consumption represents one of the key factors driving the market. Moreover, there is an increase in the utilization of cord blood banking services for the treatment of immunodeficiency disorders across the globe. This, coupled with the increasing awareness among individuals about the benefits and wide availability of cord blood banking service providers, is propelling the growth of the market. In addition, governments of several countries are extensively investing in research and development (R&D) activities to facilitate clinical trials of cord blood stem cells. In line with this, the growing number of patients with damaged bone marrow worldwide is positively influencing the market. Besides this, the rising diagnostic screening of cord blood in private centers as per guidelines and regulations of regulatory authorities is offering lucrative growth opportunities to industry investors. Additionally, the expanding healthcare industry is strengthening the growth of the market.
IMARC Group provides an analysis of the key trends in each sub-segment of the global cord blood banking services market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on component, storage services and application.
Breakup by Component:
Breakup by Storage Services:
Breakup by Application:
Breakup by Region:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Alphacord LLC, Americord Registry LLC, ATCC, California Cryobank, Cordlife Group LImited, Cryo-Cell International Inc., Global Cord Blood Corporation, LifeBank, LifeCell International Pvt. Ltd., National Cord Blood Program, Norton Healthcare Inc., Perkinelmer Inc. and StemCyte India Therapeutics Pvt. Ltd.
|Base Year of the Analysis||2021|
|Segment Coverage||Component, Storage Services, Application, Region|
|Region Covered||Asia Pacific, Europe, North America, Latin America, Middle East and Africa|
|Countries Covered||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico|
|Companies Covered||Alphacord LLC, Americord Registry LLC, ATCC, California Cryobank, Cordlife Group LImited, Cryo-Cell International Inc., Global Cord Blood Corporation, LifeBank, LifeCell International Pvt. Ltd., National Cord Blood Program, Norton Healthcare Inc., Perkinelmer Inc. and StemCyte India Therapeutics Pvt. Ltd.|
|Customization Scope||10% Free Customization|
|Report Price and Purchase Option||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support||10-12 Weeks|
|Delivery Format||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)|
Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-753-713-2163 )
( India: +91 120 433 0800 )
Drop us an email at